SCHEMBL5661332

SCHEMBL5661332

CN(C)CC(=O)N1CC=C(c2cc3c(Nc4ccccc4)ccnc3[nH]2)CC1

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CDK9 P50750 20/20 0.60
▸ CCNT1 O60563 19/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5661214 0.89 CCNT1 (0.55) CDK9CCNT1
SCHEMBL5658781 0.88 CCNT1 (0.65) CDK9CCNT1
SCHEMBL14500621 0.86 CCNT1 (0.55) CDK9CCNT1
SCHEMBL5662339 0.86 CCNT1 (0.59) CDK9CCNT1
SCHEMBL5662076 0.85 CCNT1 (0.54) CDK9CCNT1
SCHEMBL5661481 0.85 CCNT1 (0.54) CDK9CCNT1
SCHEMBL5662444 0.85 CCNT1 (0.63) CDK9CCNT1
SCHEMBL5660784 0.85 CDK9 (0.54) CDK9CCNT1
SCHEMBL5661424 0.83 CCNT1 (0.65) CDK9CCNT1
SCHEMBL14520469 0.83 CCNT1 (0.51) CDK9CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070129364-A1 Pyrrolopyridine kinase inhibiting compounds OSI PHARMACEUTICALS, INC. 2007-06-07 — — US claimed
WO-2007067537-A1 PYRROLOPYRIDINE KINASE INHIBITING COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2007-06-14 — — WO disclosed
US-20070129364-A1 Pyrrolopyridine kinase inhibiting compounds OSI PHARMACEUTICALS, INC. 2007-06-07 — — US disclosed
US-20070129364-A1 Pyrrolopyridine kinase inhibiting compounds OSI PHARMACEUTICALS, INC. 2007-06-07 — — US disclosed
US-20070129364-A1 Pyrrolopyridine kinase inhibiting compounds OSI PHARMACEUTICALS, INC. 2007-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129364-A1 Pyrrolopyridine kinase inhibiting compounds BMX, ERBB2, FRK CDK9 392/4885CCNT1 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback